Effectiveness of the Monovalent G1P[8] Human Rotavirus Vaccine Against Hospitalization for Severe G2P[4] Rotavirus Gastroenteritis in Belém, Brazil

• DOI: 10.1097/inf.0b013e3182055cc2
• Publication Date: 2010-12-10T06:01:34Z
• Authors: Maria Cleonice A....; Alexandre C. Linh...; Tatiana M. Lanzieri; Yllen Miranda; Joana D'Arc P. Ma...; Erika Abreu; Sylvia F. S. Guerra; Alessilva S. L. O...; Veronilce B. da S...; Nervo Sanchez; Nadia Meyer; Fakrudeen Shafi; Eduardo Ortega-Ba...; Montse Soriano-Ga...; Romulo E. Colindres
• Keywords: Rotavirus vaccine; Rotavirus gastroenteritis; Acute gastroenteritis

Background: Brazil initiated universal immunization of infants with the G1P[8] human rotavirus (RV) vaccine in March 2006. This study evaluated effectiveness (VE) against severe gastroenteritis (RVGE) hospitalizations. Methods: Matched case-control conducted at 4 hospitals Belém from May 2008 to 2009. Cases were children hospitalized RVGE age-eligible have received 2 doses RV (≥12 weeks age and born after 6, 2006). For each case, 1 neighborhood hospital control without was selected, matching by birth date (±8 ±6 weeks, respectively). odds ratio 2-dose vaccination cases versus controls used estimate VE (1 − × 100%). Results: Of 538 cases, 507 346 included, 54%, 61%, 74% had both doses. hospitalization 75.8% (95% confidence interval [CI]: 58.1–86.0) using 40.0% CI: 14.2–58.1) controls. 3 11 months ≥12 95.7% 67.8–99.4) 65.1% 37.2–80.6) controls, 55.6% 12.3–77.5) 32.1% −3.7–55.5) G2P[4] accounted for 82.0% G2P[4]-specific 75.4% 56.7–86.0) 38.9% 11.1–58.0) Conclusions: Although fully heterotypic predominant strain, good demonstrated. highest aged months. However, protection age, important optimal public health impact, significantly sustained based on estimates obtained